Interview with Kevin Haas (CTO, Myriad) on the next generation of diagnostics testing.

Kevin Haas discusses why Myriad’s innovations “have to be AI” in order for their diagnostics to provide the best insights for patients. He also examines why omics data is suited for AI and how the technology enables bringing the data into new contexts to lead to new innovations for therapeutics.